A survey of biases in the measurement of plasma lipid and lipoprotein concentrations in 32 lipid clinics in the UK
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Plasma lipid and lipoprotein assays have become an integral part of national strategies to detect and treat cardiovascular disease.' High plasma concentrations of total and low density lipoproteins (LDL) increase risk, whereas those of high density lipoproteins (HDL) protect. The atherogenic potential of triglycerides is controversial, but this lipid is often used to estimate LDL cholesterol concentrations.
The accuracy and precision of these assays are critical as clinical decisions are often made using nationally-defined cut-offs which do not allow for methodological error. In the case of total cholesterol these cut-offs have been lowered so that they now lie well within the normal distribution in the general population and thus their usefulness will be compromised by analytical inaccuracy. For example, a positive bias of 5OJo in a total cholesterol assay would cause misclassification of approximately 40% of patients with high or borderline-high values.? Acknowledgement of widespread inaccuracy in the measurement of total cholesterol led to the UK National Initiative on Cholesterol Accuracy, Methods and Standardization (NICAMS),3 which makes available human sera of known total cholesterol content.
The accuracy of triglyceride and HDL cholesterol assays has not been systematically investigated in the UK. We have attempted to estimate the extent of analytical biases for these analytes using data derived from a large UK multicentre study of a lipid-lowering drug."
METHODS
Fasting EDTA-plasma samples taken during the study were split into two aliquots: one analysed locally and the other sent to a central laboratory 82 (Wynn Department of Metabolic Medicine) for analysis.
These latter samples were stored for up to 3 months at -20 DC prior to transport on solid CO 2 to the central laboratory. Enzymatic assays (Cholesterol C-system, Boehringer Mannheim Ltd, East Sussex, England and Triglyceride N, Wako Chemicals GmbH, distributed by Alpha Laboratories, Hampshire, England, respectively) were used to measure total cholesterol and triglycerides at the central laboratory: HDL cholesterol was measured following precipitation of other lipoproteins by heparin and manganese ions (92 mmol/L). 5 These assays were performed by the same analyst throughout the duration of the study, using the same protocols, reagents, calibrants and analyser (Cob as MIRA S, Roche Diagnostics, Welwyn Garden City, England).
Typical between-and within-batch coefficients of variation for central laboratory assays were 2% (total cholesterol), 3% (triglycerides) and 5% (HDL cholesterol). The total cholesterol and triglyceride assays were accurate to within 3-5% of the target values assigned to commercial quality control materials. The HDL cholesterol assay has been validated against preparative ultracentrifugation. Accuracy was also assessed by analysis of samples (n = 37) obtained from Queen Elizabeth Hospital (QEH), Birmingham. The biases of the central laboratory (meansand 95% confidence intervals) from QEH were: total cholesterol, -4'1 % (-5·0 to -3,2%); triglycerides, -1· 5% (-0·03 to -2'7%)and HDL cholesterol, +2,8% (0,3 to 5· 3%). The cholesterol assay used at QEH was at that time standardized according to the criteria of USA Centers for Disease Control (R Cramb, personal communication).
RESULTS AND CONCLUSION
Local results for total cholesterol, triglyceridesand HDL cholesterol concentrations were available fell by 3-4%. Although this may cause slightly higher biases for HDL cholesterol it is unlikely to explain the overall spread of these differences.
If confirmed, these substantial biases, especially for HDL cholesterol, imply that few laboratories perform to the standard required to effectively implement national programmes for the prevention of cardiovascular disease. Miscalibration has been identified as the primary source of error in the measurement of total cholesterol and it has been shown that this bias can be reduced." Improved accuracy in triglyceride and HDL cholesterol assays awaits the availability of reference materials. The problems to be overcome include the unsuitability of lyophilized materials for HDL cholesterol assays and a lack of consensus over reference methods. For plasma total cholesterol the mean bias (regardless of sign) of local laboratories from the central laboratory was 3 . 6070, agreeing well with the figure of 4· 1% reported previously. 3 Thus, many UK laboratories exceed the target bias values of < 2-3% proposed by the USA National Cholesterol Education Panel. 6 The mean error for triglycerides (5' 5%) was approximately 50% higher than that of total cholesterol, and that of HDL cholesterol (10'6%) threefold higher. The biases of the individual laboratories varied markedly (Fig. 1) , ranging from -11·9 to + 9· 6% for total cholesterol, -13,6 to + 10·7% for triglycerides and -20·5 to + 30·2% for HDL cholesterol.
In pilot studies, total cholesterol and triglyceride were found to be stable in plasma stored frozen for over 3 months but HDL cholesterol
